Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
Top Cited Papers
- 26 July 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (16), 4986-4999
- https://doi.org/10.1021/jm800382h
Abstract
The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.Keywords
This publication has 44 references indexed in Scilit:
- Recent Developments in Fragment-Based Drug DiscoveryJournal of Medicinal Chemistry, 2008
- Fragment-based approaches to enzyme inhibitionCurrent Opinion in Biotechnology, 2007
- SPR-based fragment screening: advantages and applications.Current Topics in Medicinal Chemistry, 2007
- A decade of fragment-based drug design: strategic advances and lessons learnedNature Reviews Drug Discovery, 2007
- Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead GenerationJournal of Medicinal Chemistry, 2004
- Fragment-Based Lead Discovery Using X-ray CrystallographyJournal of Medicinal Chemistry, 2004
- Theory and Applications of NMR-Based Screening in Pharmaceutical ResearchChemical Reviews, 2004
- Ligand efficiency: a useful metric for lead selectionDrug Discovery Today, 2004
- SAR and X-ray. A New Approach Combining Fragment-Based Screening and Rational Drug Design: Application to the Discovery of Nanomolar Inhibitors of Src SH2Journal of Medicinal Chemistry, 2002
- Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug DiscoveryJournal of Chemical Information and Computer Sciences, 2001